The Library
Browse by Warwick Author
Up a level |
Jump to: Abbott Laboratories | Amis de l'Institut Bordet | Associazione Italiana Ricerca Cancro [Italian Association for Cancer Research] (AIRC) | Belgian Federation Against Cancer | Canadian Cancer Society Research Institite (CCSRI) | Cancer Research Campaign (Great Britain) (CRC) | Cancer Research UK | Cancer Research UK (CRUK) | Danish Council for Strategic Research | National Institute for Health Research (Great Britain) (NIHR) | Pfizer | Pfizer Inc. | Pharmacia & Upjohn | Pharmacia Corp. | Queen's University (Kingston, Ont.). NCIC Clinical Trials Group | Roche | Sanofi-Aventis | Scottish Breast Cancer Clinical Trials Group | Scottish Breast Cancer Trials Group | Scottish Cancer Therapy Network (SCTN) | Suomen Akatemia [Academy of Finland]
Number of items: 26.
Abbott Laboratories
HER2 TOP2A Meta-Anal Study Group (Including:
Leo, Angelo Di, Desmedt, Christine, Bartlett, John M. S., Piette, Fanny, Ejlertsen, Bent, Pritchard, Kathleen I., Larsimont, Denis, Poole, Christopher J., Isola, Jorma, Earl, Helena M. et al.
).
(2011)
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data.
Lancet Oncology, Vol.12
(No.12).
pp. 1134-1142.
doi:10.1016/S1470-2045(11)70231-5
ISSN 1470-2045.
Amis de l'Institut Bordet
HER2 TOP2A Meta-Anal Study Group (Including:
Leo, Angelo Di, Desmedt, Christine, Bartlett, John M. S., Piette, Fanny, Ejlertsen, Bent, Pritchard, Kathleen I., Larsimont, Denis, Poole, Christopher J., Isola, Jorma, Earl, Helena M. et al.
).
(2011)
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data.
Lancet Oncology, Vol.12
(No.12).
pp. 1134-1142.
doi:10.1016/S1470-2045(11)70231-5
ISSN 1470-2045.
Associazione Italiana Ricerca Cancro [Italian Association for Cancer Research] (AIRC)
HER2 TOP2A Meta-Anal Study Group (Including:
Leo, Angelo Di, Desmedt, Christine, Bartlett, John M. S., Piette, Fanny, Ejlertsen, Bent, Pritchard, Kathleen I., Larsimont, Denis, Poole, Christopher J., Isola, Jorma, Earl, Helena M. et al.
).
(2011)
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data.
Lancet Oncology, Vol.12
(No.12).
pp. 1134-1142.
doi:10.1016/S1470-2045(11)70231-5
ISSN 1470-2045.
Belgian Federation Against Cancer
HER2 TOP2A Meta-Anal Study Group (Including:
Leo, Angelo Di, Desmedt, Christine, Bartlett, John M. S., Piette, Fanny, Ejlertsen, Bent, Pritchard, Kathleen I., Larsimont, Denis, Poole, Christopher J., Isola, Jorma, Earl, Helena M. et al.
).
(2011)
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data.
Lancet Oncology, Vol.12
(No.12).
pp. 1134-1142.
doi:10.1016/S1470-2045(11)70231-5
ISSN 1470-2045.
Canadian Cancer Society Research Institite (CCSRI)
HER2 TOP2A Meta-Anal Study Group (Including:
Leo, Angelo Di, Desmedt, Christine, Bartlett, John M. S., Piette, Fanny, Ejlertsen, Bent, Pritchard, Kathleen I., Larsimont, Denis, Poole, Christopher J., Isola, Jorma, Earl, Helena M. et al.
).
(2011)
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data.
Lancet Oncology, Vol.12
(No.12).
pp. 1134-1142.
doi:10.1016/S1470-2045(11)70231-5
ISSN 1470-2045.
Cancer Research Campaign (Great Britain) (CRC)
Behalf NEAT Investigators (Including: Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, S., Harvey, P., Stanley, A., Grieve, R. J., Agrawal, R. K., Fernando, I. N., Brunt, A. M., McAdam, K., O'Reilly, S., Rea, D. W., Spooner, David A. and Poole, Christopher). (2008) NEAT : national epirubicin adjuvant trial - toxicity, delivered dose intensity and quality of life. British Journal of Cancer, Vol.99 (No.8). pp. 1226-1231. doi:10.1038/sj.bjc.6604674 ISSN 0007-0920.
Cancer Research UK
HER2 TOP2A Meta-Anal Study Group (Including:
Leo, Angelo Di, Desmedt, Christine, Bartlett, John M. S., Piette, Fanny, Ejlertsen, Bent, Pritchard, Kathleen I., Larsimont, Denis, Poole, Christopher J., Isola, Jorma, Earl, Helena M. et al.
).
(2011)
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data.
Lancet Oncology, Vol.12
(No.12).
pp. 1134-1142.
doi:10.1016/S1470-2045(11)70231-5
ISSN 1470-2045.
TACT Trial Management Grp, TACT Trialists (Including:
Ellis, Paul, Barrett-Lee, Peter, Johnson, Lindsay, Cameron, David, Wardley, Andrew, O'Reilly, Susan, Verrill, Mark, Smith, Ian, Yarnold, John, Coleman, Robert et al.
).
(2009)
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT) : an open-label, phase III, randomised controlled trial.
Lancet, Vol.373
(No.9676).
pp. 1681-1692.
doi:10.1016/S0140-6736(09)60740-6
ISSN 0140-6736.
Cancer Research UK (CRUK)
Dorling, L, Kar, Siddhartha, Michailidou, Kyriaki, Hiller, Louise, Vallier, Anne-Laure, Ingle, Susan, Hardy, Richard, Bowden, Sarah J., Dunn, Janet A., Twelves, Chris, Poole, Christopher J., Caldas, Carlos, Earl, Helena M., Pharoah, Paul D. P. and Abraham, Jean E. (2016) The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity : a case-control study. PLoS One, 11 (7). e0158984. doi:10.1371/journal.pone.0158984 ISSN 1932-6203.
Bartlett, John M. S., Munro, Alison F., Dunn, Janet A., McConkey, Christopher C., Jordan, S., Twelves, Chris, Cameron, D., Thomas, Jeremy St. J., Campbell, Fiona M., Rea, Daniel W., Provenzano, Elena, Caldas, Carlos, Pharaoh, Paul, Hiller, Louise, Earl, Helena M. and Poole, Christopher (2010) Predictive markers of anthracycline benefit : a prospectively planned analysis of the UK national epirubicin adjuvant trial (NEAT/BR9601). Lancet Oncology, Vol.11 (No.3). pp. 266-274. doi:10.1016/S1470-2045(10)70006-1 ISSN 1470-2045.
Poole, Christopher J., Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, Sarah, Grieve, Robert J., Spooner, David A., Agrawal, Rajiv K., Brunt, A. Murray, OβReilly, Susan M. et al.
(2006)
Epirubicin and cyclophosphamide, methotrexate,
and fluorouracil as adjuvant therapy for early breast cancer.
New England Journal of Medicine, Vol.355
(No.18).
pp. 1851-1862.
doi:10.1056/NEJMoa052084
ISSN 0028-4793.
Danish Council for Strategic Research
HER2 TOP2A Meta-Anal Study Group (Including:
Leo, Angelo Di, Desmedt, Christine, Bartlett, John M. S., Piette, Fanny, Ejlertsen, Bent, Pritchard, Kathleen I., Larsimont, Denis, Poole, Christopher J., Isola, Jorma, Earl, Helena M. et al.
).
(2011)
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data.
Lancet Oncology, Vol.12
(No.12).
pp. 1134-1142.
doi:10.1016/S1470-2045(11)70231-5
ISSN 1470-2045.
National Institute for Health Research (Great Britain) (NIHR)
Dorling, L, Kar, Siddhartha, Michailidou, Kyriaki, Hiller, Louise, Vallier, Anne-Laure, Ingle, Susan, Hardy, Richard, Bowden, Sarah J., Dunn, Janet A., Twelves, Chris, Poole, Christopher J., Caldas, Carlos, Earl, Helena M., Pharoah, Paul D. P. and Abraham, Jean E. (2016) The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity : a case-control study. PLoS One, 11 (7). e0158984. doi:10.1371/journal.pone.0158984 ISSN 1932-6203.
Pfizer
TACT Trial Management Grp, TACT Trialists (Including:
Ellis, Paul, Barrett-Lee, Peter, Johnson, Lindsay, Cameron, David, Wardley, Andrew, O'Reilly, Susan, Verrill, Mark, Smith, Ian, Yarnold, John, Coleman, Robert et al.
).
(2009)
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT) : an open-label, phase III, randomised controlled trial.
Lancet, Vol.373
(No.9676).
pp. 1681-1692.
doi:10.1016/S0140-6736(09)60740-6
ISSN 0140-6736.
Pfizer Inc.
HER2 TOP2A Meta-Anal Study Group (Including:
Leo, Angelo Di, Desmedt, Christine, Bartlett, John M. S., Piette, Fanny, Ejlertsen, Bent, Pritchard, Kathleen I., Larsimont, Denis, Poole, Christopher J., Isola, Jorma, Earl, Helena M. et al.
).
(2011)
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data.
Lancet Oncology, Vol.12
(No.12).
pp. 1134-1142.
doi:10.1016/S1470-2045(11)70231-5
ISSN 1470-2045.
Poole, Christopher J., Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, Sarah, Grieve, Robert J., Spooner, David A., Agrawal, Rajiv K., Brunt, A. Murray, OβReilly, Susan M. et al.
(2006)
Epirubicin and cyclophosphamide, methotrexate,
and fluorouracil as adjuvant therapy for early breast cancer.
New England Journal of Medicine, Vol.355
(No.18).
pp. 1851-1862.
doi:10.1056/NEJMoa052084
ISSN 0028-4793.
Pharmacia & Upjohn
HER2 TOP2A Meta-Anal Study Group (Including:
Leo, Angelo Di, Desmedt, Christine, Bartlett, John M. S., Piette, Fanny, Ejlertsen, Bent, Pritchard, Kathleen I., Larsimont, Denis, Poole, Christopher J., Isola, Jorma, Earl, Helena M. et al.
).
(2011)
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data.
Lancet Oncology, Vol.12
(No.12).
pp. 1134-1142.
doi:10.1016/S1470-2045(11)70231-5
ISSN 1470-2045.
Pharmacia Corp.
Bartlett, John M. S., Munro, Alison F., Dunn, Janet A., McConkey, Christopher C., Jordan, S., Twelves, Chris, Cameron, D., Thomas, Jeremy St. J., Campbell, Fiona M., Rea, Daniel W., Provenzano, Elena, Caldas, Carlos, Pharaoh, Paul, Hiller, Louise, Earl, Helena M. and Poole, Christopher (2010) Predictive markers of anthracycline benefit : a prospectively planned analysis of the UK national epirubicin adjuvant trial (NEAT/BR9601). Lancet Oncology, Vol.11 (No.3). pp. 266-274. doi:10.1016/S1470-2045(10)70006-1 ISSN 1470-2045.
Behalf NEAT Investigators (Including: Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, S., Harvey, P., Stanley, A., Grieve, R. J., Agrawal, R. K., Fernando, I. N., Brunt, A. M., McAdam, K., O'Reilly, S., Rea, D. W., Spooner, David A. and Poole, Christopher). (2008) NEAT : national epirubicin adjuvant trial - toxicity, delivered dose intensity and quality of life. British Journal of Cancer, Vol.99 (No.8). pp. 1226-1231. doi:10.1038/sj.bjc.6604674 ISSN 0007-0920.
Queen's University (Kingston, Ont.). NCIC Clinical Trials Group
HER2 TOP2A Meta-Anal Study Group (Including:
Leo, Angelo Di, Desmedt, Christine, Bartlett, John M. S., Piette, Fanny, Ejlertsen, Bent, Pritchard, Kathleen I., Larsimont, Denis, Poole, Christopher J., Isola, Jorma, Earl, Helena M. et al.
).
(2011)
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data.
Lancet Oncology, Vol.12
(No.12).
pp. 1134-1142.
doi:10.1016/S1470-2045(11)70231-5
ISSN 1470-2045.
Roche
TACT Trial Management Grp, TACT Trialists (Including:
Ellis, Paul, Barrett-Lee, Peter, Johnson, Lindsay, Cameron, David, Wardley, Andrew, O'Reilly, Susan, Verrill, Mark, Smith, Ian, Yarnold, John, Coleman, Robert et al.
).
(2009)
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT) : an open-label, phase III, randomised controlled trial.
Lancet, Vol.373
(No.9676).
pp. 1681-1692.
doi:10.1016/S0140-6736(09)60740-6
ISSN 0140-6736.
Sanofi-Aventis
TACT Trial Management Grp, TACT Trialists (Including:
Ellis, Paul, Barrett-Lee, Peter, Johnson, Lindsay, Cameron, David, Wardley, Andrew, O'Reilly, Susan, Verrill, Mark, Smith, Ian, Yarnold, John, Coleman, Robert et al.
).
(2009)
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT) : an open-label, phase III, randomised controlled trial.
Lancet, Vol.373
(No.9676).
pp. 1681-1692.
doi:10.1016/S0140-6736(09)60740-6
ISSN 0140-6736.
Scottish Breast Cancer Clinical Trials Group
Bartlett, John M. S., Munro, Alison F., Dunn, Janet A., McConkey, Christopher C., Jordan, S., Twelves, Chris, Cameron, D., Thomas, Jeremy St. J., Campbell, Fiona M., Rea, Daniel W., Provenzano, Elena, Caldas, Carlos, Pharaoh, Paul, Hiller, Louise, Earl, Helena M. and Poole, Christopher (2010) Predictive markers of anthracycline benefit : a prospectively planned analysis of the UK national epirubicin adjuvant trial (NEAT/BR9601). Lancet Oncology, Vol.11 (No.3). pp. 266-274. doi:10.1016/S1470-2045(10)70006-1 ISSN 1470-2045.
Scottish Breast Cancer Trials Group
HER2 TOP2A Meta-Anal Study Group (Including:
Leo, Angelo Di, Desmedt, Christine, Bartlett, John M. S., Piette, Fanny, Ejlertsen, Bent, Pritchard, Kathleen I., Larsimont, Denis, Poole, Christopher J., Isola, Jorma, Earl, Helena M. et al.
).
(2011)
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data.
Lancet Oncology, Vol.12
(No.12).
pp. 1134-1142.
doi:10.1016/S1470-2045(11)70231-5
ISSN 1470-2045.
Scottish Cancer Therapy Network (SCTN)
Bartlett, John M. S., Munro, Alison F., Dunn, Janet A., McConkey, Christopher C., Jordan, S., Twelves, Chris, Cameron, D., Thomas, Jeremy St. J., Campbell, Fiona M., Rea, Daniel W., Provenzano, Elena, Caldas, Carlos, Pharaoh, Paul, Hiller, Louise, Earl, Helena M. and Poole, Christopher (2010) Predictive markers of anthracycline benefit : a prospectively planned analysis of the UK national epirubicin adjuvant trial (NEAT/BR9601). Lancet Oncology, Vol.11 (No.3). pp. 266-274. doi:10.1016/S1470-2045(10)70006-1 ISSN 1470-2045.
Suomen Akatemia [Academy of Finland]
HER2 TOP2A Meta-Anal Study Group (Including:
Leo, Angelo Di, Desmedt, Christine, Bartlett, John M. S., Piette, Fanny, Ejlertsen, Bent, Pritchard, Kathleen I., Larsimont, Denis, Poole, Christopher J., Isola, Jorma, Earl, Helena M. et al.
).
(2011)
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data.
Lancet Oncology, Vol.12
(No.12).
pp. 1134-1142.
doi:10.1016/S1470-2045(11)70231-5
ISSN 1470-2045.
This list was generated on Tue Mar 19 01:54:48 2024 GMT.